• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors

    12/15/22 7:00:00 AM ET
    $GERN
    $MRNA
    $PFE
    $RVMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GERN alert in real time by email

    Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE: PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ:GERN), vice president of oncology at Genentech (part of the Roche Group) and medical director at Pharmacia / SUGEN (acquired by Pfizer). Dr. Kelsey has had key roles in the development of many oncology therapeutics including Sutent®, Perjeta®, Kadcycla®, Erivedge® and imetelstat.

    "I'm delighted to welcome Steve to our Board," said David J. Earp, JD, PhD, Circle's president and CEO. "We expect to initiate IND-enabling studies in our lead program, an orally bioavailable cyclin A inhibitor, in 2023, and are building the clinical team that will support this program as it enters clinical development. In parallel, we are progressing our pipeline of other targeted oncology therapeutics. Steve has extensive experience in early oncology clinical development, including building successful development teams, and I look forward to working with him closely as Circle progresses to become a clinical-stage company."

    "Circle's macrocycle platform offers a new approach to important oncology targets that have proven refractory to other modalities, and I have been impressed by the quality of the pre-clinical work and the broad clinical potential of the company's lead cyclin A program," noted Dr. Kelsey. "I'm excited to join Circle's Board and to help the company bring its promising therapies to cancer patients."

    Dr. Kelsey received his medical degrees from the University of Birmingham in the UK and trained as a hematologic oncologist at Barts and The London Hospital where he was a clinician-scientist focused in leukemias and lymphomas.

    About Circle Pharma, Inc.

    Circle has developed a platform that combines structure-based rational drug design and advanced synthetic chemistry to develop first-in-class macrocycle therapeutics for challenging targets to address unmet clinical needs. Circle's technology facilitates the design and synthesis of intrinsically cell-permeable macrocycles that can address both intra- and extra-cellular therapeutic targets, and can be delivered by multiple routes, including oral administration. Circle's macrocycle drug discovery & development platform is applicable across a wide range of serious diseases; the company is initially focusing its development efforts on intracellular protein-protein interactions that are key drivers in cancer. Its pipeline includes programs targeting cyclin proteins, including cyclins A, E and D, which are part of the regulatory machinery that controls progression of cells through the cell cycle. Inhibition of cyclin A was originally reported to be synthetic lethal to cancer cells that carry mutations causing dysregulation of the Rb pathway – such mutations are frequently found in small cell lung cancer. Circle has demonstrated that its cyclin A inhibitor program has the potential to cause significant tumor regression in multiple additional solid and hematologic cancers.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005026/en/

    Get the next $GERN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GERN
    $MRNA
    $PFE
    $RVMD

    CompanyDatePrice TargetRatingAnalyst
    Revolution Medicines Inc.
    $RVMD
    10/21/2025$90.00Outperform
    Mizuho
    Revolution Medicines Inc.
    $RVMD
    10/16/2025$85.00Buy
    Stifel
    Revolution Medicines Inc.
    $RVMD
    9/12/2025$72.00Strong Buy
    Raymond James
    Revolution Medicines Inc.
    $RVMD
    9/5/2025$99.00Buy
    Truist
    Revolution Medicines Inc.
    $RVMD
    8/19/2025$75.00Overweight
    Piper Sandler
    Revolution Medicines Inc.
    $RVMD
    8/15/2025$67.00Overweight
    Wells Fargo
    Revolution Medicines Inc.
    $RVMD
    7/15/2025$65.00Buy
    Goldman
    Geron Corporation
    $GERN
    7/10/2025$1.00Sell
    Goldman
    More analyst ratings

    $GERN
    $MRNA
    $PFE
    $RVMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Revolution Medicines with a new price target

    Mizuho initiated coverage of Revolution Medicines with a rating of Outperform and set a new price target of $90.00

    10/21/25 7:22:03 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stifel resumed coverage on Revolution Medicines with a new price target

    Stifel resumed coverage of Revolution Medicines with a rating of Buy and set a new price target of $85.00

    10/16/25 8:28:24 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James resumed coverage on Revolution Medicines with a new price target

    Raymond James resumed coverage of Revolution Medicines with a rating of Strong Buy and set a new price target of $72.00

    9/12/25 7:52:44 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GERN
    $MRNA
    $PFE
    $RVMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lawlis V Bryan bought $15,667 worth of shares (13,300 units at $1.18) (SEC Form 4)

    4 - GERON CORP (0000886744) (Issuer)

    5/13/25 4:20:43 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GERN
    $MRNA
    $PFE
    $RVMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards on (i) October 17, 2025, covering an aggregate of 1,579,500 shares of its common stock, consisting of stock options to purchase an aggregate of 1,553,000 shares of common stock, and restricted stock units ("RSUs") representing an aggregate of 26,500 shares of common stock, to three newly hired employees and (ii) October 20, 2025, covering an aggregate of 1,500,000 shares of its common stock to one newly hired employee, each as an inducement material to their acceptance of employment with Geron. The stock options granted on October 17, 2025 have an exercise price

    10/20/25 5:32:00 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

    – Data demonstrated that vepdegestrant maintained patients' quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including pain, compared to fulvestrant –  NEW HAVEN, Conn., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), today announced new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant, which are being presented in a mini oral session at the 2025 European Society for Medical Oncology (ESMO) Congress. Vepdegestrant is a novel investigational PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader which is being de

    10/20/25 4:15:00 AM ET
    $ARVN
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer

    The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence1 XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting Final results from the Phase 3 EMBARK study are being presented in a late-breaking oral session at ESMO 2025 and simultaneously published in The New England Journal of Medicine Pfizer Inc. (NYSE:PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") tod

    10/19/25 4:15:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    $MRNA
    $PFE
    $RVMD
    SEC Filings

    View All

    SEC Form SC TO-C filed by Moderna Inc.

    SC TO-C - Moderna, Inc. (0001682852) (Subject)

    10/21/25 4:33:25 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Revolution Medicines Inc.

    144 - Revolution Medicines, Inc. (0001628171) (Subject)

    10/17/25 4:18:38 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Revolution Medicines Inc.

    8-K - Revolution Medicines, Inc. (0001628171) (Filer)

    10/16/25 8:27:17 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GERN
    $MRNA
    $PFE
    $RVMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP, Chief Commercial Officer Elnawawi Ahmed

    4 - GERON CORP (0000886744) (Issuer)

    10/20/25 5:35:05 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Elnawawi Ahmed claimed ownership of 10,000 shares (SEC Form 3)

    3 - GERON CORP (0000886744) (Issuer)

    10/20/25 5:07:28 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    10/17/25 5:19:03 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    $MRNA
    $PFE
    $RVMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    $MRNA
    $PFE
    $RVMD
    Leadership Updates

    Live Leadership Updates

    View All

    Geron Corporation Announces Executive Leadership Transitions and Appointments

    FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transitions and appointments designed to align the company's leadership structure with its strategic priorities. Andrew Grethlein, Ph.D. who joined Geron in September 2012 and has served as Executive Vice President, Chief Operating Officer since January 2019, will depart the company on October 15, 2025, transitioning to a consulting role, while pursuing other interests. Jim Ziegler, who joined the company in September 2024 as Executive Vice President, Chief Commer

    10/13/25 4:34:48 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

    Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T

    9/30/25 12:45:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

    REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role of chief development officer, as well as the appointment of regional general managers in the U.S. and Europe. "I am delighted to welcome Alan as our chief development officer as we pursue our bold vision to develop new global standards of care for patients with RAS-addicted cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "As a physician-

    9/29/25 9:00:15 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GERN
    $MRNA
    $PFE
    $RVMD
    Financials

    Live finance-specific insights

    View All

    Pfizer Declares Fourth-Quarter 2025 Dividend

    Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company's common stock, payable December 1, 2025, to holders of the Common Stock of record at the close of business on November 7, 2025. The fourth-quarter 2025 cash dividend will be the 348th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discov

    10/9/25 4:30:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 4, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Third Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the confer

    9/23/25 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

    Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer's pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an initial enterprise value of $4.9 billion with a CVR of up to $22.50 per share in additional payments Pfizer to host a public webcast at 8 am EDT today Pfizer Inc. (NYSE:PFE) and Metsera, Inc. (NASDAQ:MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a

    9/22/25 6:45:00 AM ET
    $MTSR
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GERN
    $MRNA
    $PFE
    $RVMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Geron Corporation

    SC 13G/A - GERON CORP (0000886744) (Subject)

    11/14/24 5:46:12 PM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Geron Corporation

    SC 13G/A - GERON CORP (0000886744) (Subject)

    11/14/24 9:31:41 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Geron Corporation

    SC 13G - GERON CORP (0000886744) (Subject)

    11/14/24 6:25:29 AM ET
    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care